Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK3 | Q9NZJ5 | 9/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 8/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | EIF2AK2 | P19525 | 4/20 | 0.47 |
| ▸ | EIF2AK1 | Q9BQI3 | 4/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | EIF2AK4 | Q9P2K8 | 2/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | EGFR | P00533 | 3/20 | 0.42 |
| ▸ | LCK | P06239 | 3/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.41 |
| ▸ | HCK | P08631 | 2/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30120848 | 1.00 | EIF2AK3 (0.47) | EIF2AK3RIPK1CYP3A4EIF2AK2EIF2AK1 | |
| SCHEMBL25793432 | 0.94 | RIPK1 (0.48) | EIF2AK3RIPK1CYP3A4EIF2AK2EIF2AK1 | |
| SCHEMBL30120757 | 0.88 | RIPK1 (0.49) | EIF2AK3RIPK1CYP3A4EIF2AK2EIF2AK1 | |
| SCHEMBL24650623 | 0.88 | RIPK1 (0.49) | EIF2AK3RIPK1CYP3A4EIF2AK2EIF2AK1 | |
| SCHEMBL30120865 | 0.87 | EIF2AK3 (0.47) | EIF2AK3RIPK1CYP3A4EIF2AK2EIF2AK1 | |
| SCHEMBL24650628 | 0.87 | EIF2AK3 (0.47) | EIF2AK3RIPK1CYP3A4EIF2AK2EIF2AK1 | |
| SCHEMBL24650641 | 0.85 | EIF2AK3 (0.51) | EIF2AK3RIPK1CYP3A4EIF2AK2EIF2AK1 | |
| SCHEMBL30120832 | 0.85 | EIF2AK3 (0.51) | EIF2AK3RIPK1CYP3A4EIF2AK2EIF2AK1 | |
| SCHEMBL24650626 | 0.85 | EIF2AK3 (0.50) | EIF2AK3RIPK1CYP3A4EIF2AK2EIF2AK1 | |
| SCHEMBL30120857 | 0.85 | EIF2AK3 (0.50) | EIF2AK3RIPK1CYP3A4EIF2AK2EIF2AK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| WO-2022212326-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | EIF2AK3 1310/4885RIPK1 20/4885CYP3A4 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.